Barocas Daniel A, Rabbani Farhang, Scherr Douglas S, Vaughan E Darracott
Department of Urology, James Buchanan Brady Foundation, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA.
BJU Int. 2006 Jan;97(1):33-6. doi: 10.1111/j.1464-410X.2005.05880.x.
To investigate the incidence of prostate cancer in men with renal cell carcinoma (RCC) and the incidence of RCC in men with prostate cancer.
We evaluated the database of the Surveillance, Epidemiology and End Results Program of the National Cancer Institute from 1973 to 1996, to calculate the incidence of RCC in men with prostate cancer and the incidence of prostate cancer in men with RCC. The standardized incidence ratio (SIR, observed/expected) was calculated for each of the scenarios of interest, as well as for RCC and prostate cancer in men with other common malignancies. Lung/bronchus cancer, colon/rectal cancer, and non-Hodgkin lymphoma were selected for the control scenarios because they are the most common non-urological cancers among men in the USA.
There was a higher incidence of RCC in men with prostate cancer (SIR 1.25, P < 0.01). RCC incidence was also higher in men with each of the other malignancies. Prostate cancer incidence was higher in men with RCC (SIR 1.42, P < 0.001), but was not significantly elevated for any of the control scenarios.
The incidence of RCC is higher in men with each of the index cancers, whereas that for prostate cancer was higher only in men with RCC. A common aetiological factor is possible. However, it is also possible that detection bias explains these findings. Serial imaging might increase the detection of RCC among patients with a variety of index malignancies. Patients with RCC who are followed by a urologist might be screened more rigorously for prostate cancer than patients with other primary malignancies, leading to increased detection in these men.
研究肾细胞癌（RCC）男性患者中前列腺癌的发病率以及前列腺癌男性患者中RCC的发病率。
我们评估了美国国立癌症研究所监测、流行病学和最终结果计划1973年至1996年的数据库，以计算前列腺癌男性患者中RCC的发病率以及RCC男性患者中前列腺癌的发病率。针对每种感兴趣的情况以及患有其他常见恶性肿瘤的男性中的RCC和前列腺癌，计算标准化发病率比（SIR，观察值/预期值）。选择肺癌/支气管癌、结肠癌/直肠癌和非霍奇金淋巴瘤作为对照情况，因为它们是美国男性中最常见的非泌尿系统癌症。
前列腺癌男性患者中RCC的发病率较高（SIR 1.25，P < 0.01）。其他每种恶性肿瘤男性患者中的RCC发病率也较高。RCC男性患者中前列腺癌的发病率较高（SIR 1.42，P < 0.001），但在任何对照情况中均未显著升高。
每种索引癌症男性患者中RCC的发病率较高，而前列腺癌仅在RCC男性患者中发病率较高。可能存在共同的病因因素。然而，检测偏倚也可能解释这些发现。系列成像可能会增加各种索引恶性肿瘤患者中RCC的检出率。由泌尿科医生随访的RCC患者可能比其他原发性恶性肿瘤患者接受更严格的前列腺癌筛查，从而导致这些男性中检出率增加。
